Condition
Sarcomatoid Carcinoma
Total Trials
5
Recruiting
2
Active
2
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 85/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
50% success
Data Visualizations
Phase Distribution
3Total
P 1 (1)
P 2 (2)
Trial Status
Recruiting2
Unknown1
Terminated1
Completed1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT06683846Phase 2Recruiting
Ivonescimab in the Treatment of Multiple Advanced Tumors
NCT06950814RecruitingPrimary
Prognostic Impact of Adjuvant Therapy in Primary Hepatic Sarcomatoid Carcinoma
NCT05337163Completed
A Multicenter Clinical Trial of Sputum DNA Testing for Lung Cancer in China
NCT05265793Phase 2Unknown
Camrelizumab Combined With Apatinib in the Treatment of Advanced Sarcomatoid Carcinoma or Carcinosarcoma
NCT02029690Phase 1Terminated
Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin
Showing all 5 trials